Non-IO and IO Partnering and Development: What's the Role of Non-IO in an IO World?

This whitepaper discusses the role of non-immuno-oncology therapies for cancer in a world where immuno-oncology is playing a greater role.

The clinical success of checkpoint inhibitors has made Immuno-Oncology an amazingly "hot" area for pharmaceutical and biotech deal-making. With checkpoint antibodies seen as backbones for combination therapy in cancer, many in Oncology are asking:

  • What is the role of non-IO in an IO world and can you partner a non-IO opportunity?

  • Is there still room for new anticancer agents that are not working in IO models?

  • Are drug candidates evaluated with the assumption that everything will eventually be used in combination with IO agents? Or are there indications or mechanisms for which IO will never be important?  Should I pursue combinations with IO?

  • What kinds of mechanisms are attractive in non-IO? What data and models will big pharma want to see? Do I need to run experiments with their molecule? Are there certain tumor types that are particularly attractive?

  • Is it too late to try to compete in the crowded space of combination with PD1 antibodies?  What other IO agents are likely to backbones of oncology franchises?

  • What will make my non-IO drug candidate compelling for partners and investors?


 

VIEW THE
WHITEPAPER

WHITEPAPER   Authors:

Company team

Linda Pullan, PhD - Moderator

Pullan Consulting

Linda offers biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a Ph.D. in Biochemistry, a B.S. in Chemistry, and more than twenty years of drug industry experience. Learn More

Company team

Jeff Bockman, PhD

EVP, Oncology Practice Head, Cello Health BioConsulting

Jeff leads the Oncology Practice at Cello Health BioConsulting. He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn More

Company team

Peter Sandor, MD, MBA

Vice President and Head Oncology Marketing Strategy, Astellas

Peter brings 19 years of progressive marketing experience, having held positions as VP, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen’s oncology assets and Head of Strategy and Portfolio Management at Bayer Healthcare. Learn More

Company team

Axel Hoos, MD, PhD

Vice President, Oncology R&D and Head of Immuno-Oncology at GlaxoSmithKline Pharmaceuticals (GSK)

Axel builds the immuno-oncology portfolio of GSK across the modalities of antibodies, small molecules, bispecific molecules and cell & gene therapies, for which he directs clinical and discovery research. Learn More

Company team

Eric Haura, MD

Sr Member, Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL

Eric receive his BS in biomedical engineering from Johns Hopkins University, completed medical school at Duke University School of Medicine, completed a residency program in internal medicine at Johns Hopkins, and then returned to Duke to pursue a clinical fellowship in hematology and oncology. Learn More


Sponsored by: